Indaptus director Tim Ruan resigns immediately
Indaptus Therapeutics, Inc. reports the immediate resignation of director Tim Ruan, stating there was no disagreement with the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Indaptus Therapeutics, Inc. (INDP) announced that on September 2, 2026, director Tim Ruan notified the company’s Board of Directors of his resignation, effective immediately. The company states that his resignation was not due to any disagreement regarding operations, policies, or practices.
The report is signed on behalf of Indaptus Therapeutics, Inc. by Chief Executive Officer Junyi Dai. Indaptus’s common stock, with a par value of $0.01 per share, is listed on the Nasdaq Capital Market under the symbol INDP.
Insights
Analyzing...
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Resignation notification date: September 2, 2026
Form 8-K signature date: September 4, 2026
Par value per common share: $0.01
+2 more
5 metrics
Resignation notification date
September 2, 2026
Date director Tim Ruan notified the Board of his resignation
Form 8-K signature date
September 4, 2026
Date the report was signed by CEO Junyi Dai
Par value per common share
$0.01
Par value of Indaptus Therapeutics, Inc. common stock
Trading symbol
INDP
Nasdaq Capital Market listing symbol for common stock
Principal office phone number
(646) 427-2727
Registrant’s telephone number including area code
Key Terms
Emerging growth company, Nasdaq Capital Market, Inline XBRL, Exchange Act
4 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nasdaq Capital Market market
"Name of each exchange on which registered Common Stock, $0.01 par value | | INDP | | Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Exchange Act regulatory
"pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)"
A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What director change did INDP report on September 2, 2026?
Indaptus Therapeutics, Inc. reported that director Tim Ruan resigned from the Board on September 2, 2026, effective immediately. The company stated that his resignation was not the result of any disagreement with the company’s operations, policies, or practices.
Did Tim Ruan resign from INDP’s board due to a disagreement?
No. Indaptus Therapeutics, Inc. stated that Mr. Ruan’s resignation was not the result of any disagreement with the company on matters related to its operations, policies, or practices.
What stock exchange lists Indaptus Therapeutics, Inc. (INDP)?
Indaptus Therapeutics, Inc.’s common stock is listed on the Nasdaq Capital Market under the trading symbol INDP, with a par value of $0.01 per share.
Who signed the September 2026 Form 8-K for INDP?
The Form 8-K was signed on behalf of Indaptus Therapeutics, Inc. by Junyi Dai, who is identified as the company’s Chief Executive Officer, dated September 4, 2026.
When was the INDP director resignation disclosed and made effective?
Indaptus Therapeutics, Inc. reports that on September 2, 2026, director Tim Ruan notified the Board of his resignation and that it was effective immediately on that same date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
